ORGANIGRAM GLOBAL INC.
OGI · Pharmaceutical Preparations · EDGAR filings ↗
Grade
D51Canadian cannabis producer with a strong, BAT-backed balance sheet but persistent losses and compressed margins.
Strengths
- Pristine balance sheet: current ratio 4.9, near-zero debt; BAT strategic backing
- Slightly positive operating cash flow (71st pct)
Risks
- Net margin -28%, operating margin -22%, ROE -14.8%; net income fell 82%
- Low gross margin (11th pct) and declining revenue in a price-pressured market
Notable findings
- Net lossNet loss (net margin -28.4%)
- Cash burnNegative free cash flow (-0.6M)
- Notable holderHeld by 3 notable fund(s): RENAISSANCE TECHNOLOGIES LLC, GOLDMAN SACHS GROUP INC, CITADEL ADVISORS LLC (as of 2026-03-31)
Key metrics
Gross margin
29.7%
Operating margin
-22.3%
Net margin
-28.4%
Return on equity
-14.9%
Return on assets
-11.1%
ROIC
-9.2%
Revenue growth (QoQ)
-1.8%
Debt / equity
0.0×
Current ratio
4.9×
Free cash flow
-$635K
Tangible book value
$226M
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 40-F | 2025-12-16 | 2025-09-30 | 0001628280-25-057233 ↗ |
| 40-F | 2024-12-18 | 2024-09-30 | 0001628280-24-051826 ↗ |
| 40-F | 2023-12-19 | 2023-09-30 | 0001628280-23-041900 ↗ |
| 40-F | 2022-11-29 | 2022-08-31 | 0001628280-22-030921 ↗ |
| 40-F | 2021-11-23 | 2021-08-31 | 0001062993-21-011478 ↗ |
| 40-F | 2020-11-30 | 2020-08-31 | 0001062993-20-005949 ↗ |
| 40-F | 2019-11-27 | 2019-08-31 | 0001062993-19-004607 ↗ |